根据美国药品研究与制造商协会(the Pharmaceutical Research and Manufacturers of Amecica，PhRMA)的统计，目前进入临床研究阶段或FDA审批程序的用于糖尿病的药物有183个。这些在研药物中用于1型糖尿病的有26个，用于2型糖尿病的有133个，用于糖尿病相关性疾病的有19个，还有未确定何种糖尿病的有15个(注：一些药物被列入多个治疗类别)。
1 1型和2型糖尿病
|
产品名称 |
公司 |
适应证 |
研发阶段 | |
|
11ßHSD抑制剂 |
Bristol-Myers Squibb |
糖尿病 |
临床研究中 | |
|
376501(PPAR gamma部分激动剂) |
GlaxoSmithKline |
2型糖尿病 |
I期临床 | |
|
625019(PPAR pan激动剂) |
GlaxoSmithKline |
2型糖尿病 |
I期临床 | |
|
756050 |
GlaxoSmithKline |
2型糖尿病 |
I期临床 | |
|
1292263 |
GlaxoSmithKline |
2型糖尿病 |
I期临床 | |
|
1614235 |
GlaxoSmithKline |
2型糖尿病 |
I期临床 | |
|
ABT-279 |
Abbott Laboratories |
2型糖尿病 |
I期临床 | |
|
Afresa(胰岛素吸入剂) |
MannKind |
1型糖尿病 2型糖尿病 |
提交申请 | |
|
AI-401 |
AutoImmune |
1型糖尿病 (预防) |
III期临床 | |
|
Albulin(albumin/insulin) |
Teva Pharmaceuticals |
1型糖尿病 2型糖尿病 |
I期临床 | |
|
alogliptin |
Takeda Pharmaceuticals |
2型糖尿病 |
提交申请 | |
|
alogliptin/pioglitazone (固定剂量复方) |
Takeda Pharmaceuticals |
2型糖尿病 |
提交申请 | |
|
Altace(雷米普利，ramipril) |
King Pharmaceuticals |
2型糖尿病 (预防) |
III期临床 | |
|
Alveair(胰岛素吸入剂) |
Coremed |
糖尿病 |
I期临床 | |
|
AMG 108 |
Amgen |
糖尿病 |
II期临床 | |
|
AMG 221 |
Amgen |
2型糖尿病 |
I期临床 | |
|
AMG 222 |
Amgen |
2型糖尿病 |
II期临床 | |
|
AMG 477 |
Amgen |
2型糖尿病 |
I期临床 | |
|
APD597 |
Arena Pharmaceuticals，Johnson & Johnson Pharmaceutical Research & Development |
2型糖尿病 |
I期临床 | |
|
Apidra SoloSTAR(格鲁辛胰岛素一次性注射笔) |
Sanofi-Aventis |
1型糖尿病 2型糖尿病 |
提交申请 | |
|
AR9281 |
Arete Therapeutics |
2型糖尿病 |
II期临床 | |
|
ARI-2243 |
Arisaph Pharmaceuticals |
2型糖尿病 |
I期临床 | |
|
ARRY-403 |
Array BioPharma |
2型糖尿病 |
I期临床 | |
|
AT1391(胰岛素贴剂) |
Altea Therapeutics |
1型糖尿病 |
I/II期临床 | |
|
2型糖尿病 |
I期临床 | |||
|
ATL-844 |
PGxHealth |
2型糖尿病 |
II期临床 | |
|
Avandamet XR (罗格列酮/二甲双胍缓释制剂) |
GlaxoSmithKline |
2型糖尿病 |
III期临床 | |
|
Avandia(罗格列酮) |
GlaxoSmithKline |
2型糖尿病 (预防) |
III期临床 | |
|
AVE0010(GLP1激动剂) |
Sanofi-Aventis |
2型糖尿病 |
III期临床 | |
|
AVE0897(PPAR激动剂) |
Sanofi-Aventis |
2型糖尿病 |
I期临床 | |
|
AVR 118 |
Advanced Viral Research |
2型糖尿病 |
I期临床完成 | |
|
AZD1656 |
AstraZeneca |
2型糖尿病 |
II期临床 | |
|
1型糖尿病 |
I期临床 | |||
|
AZD4017 |
AstraZeneca |
2型糖尿病 |
I期临床 | |
|
AZD6370 |
AstraZeneca |
2型糖尿病 |
II期临床 | |
|
balaglitazone |
Dr. Reddy’s Laboratories |
2型糖尿病 |
III期临床 | |
|
basal insulin analog (基础胰岛素类似物) |
Eli Lilly |
糖尿病 |
I期临床 | |
|
BAY 73-7977 |
Bayer HealthCare Pharmaceuticals |
糖尿病 |
I期临床 | |
|
BGP15 |
N-Gene Research Laboratories |
2型糖尿病 |
II期临床完成 | |
|
BHT-3021 |
Bayhill Therapeutics，Juvenile Diabetes Research Foundation |
1型糖尿病 |
I/II期临床 | |
|
BI-10773 |
Boehringer Ingelheim Pharmaceuticals |
2型糖尿病 |
II期临床 | |
|
BI-44847 |
Boehringer Ingelheim Pharmaceuticals |
2型糖尿病 |
II期临床 | |
|
Byetta(exenatide) |
Amylin Pharmaceuticals， Eli Lilly |
2型糖尿病 (单一药物治疗) |
提交申请 | |
|
2型糖尿病(青少年) |
II期临床 | |||
|
canakinumab |
Novartis Pharmaceuticals |
2型糖尿病 |
II/III期临床 | |
|
CCR2 拮抗剂 |
Bristol-Myers Squibb |
糖尿病 |
临床研究中 | |
|
CE-326597 |
Pfizer |
2型糖尿病 |
II期临床 | |
|
cetilistat |
Alizyme |
2型糖尿病 (肥胖症者) |
II期临床 | |
|
CRx-401 |
CombinatoRx |
2型糖尿病 |
II期临床 | |
|
CVT-3619 |
CV Therapeutics |
糖尿病 |
I期临床 | |
|
Cycloset |
S2 Therapeutics |
2型糖尿病 |
III期临床 | |
|
dapagliflozin(SGLT2抑制剂) |
AstraZeneca， Bristol-Myers Squibb |
糖尿病 |
III期临床 | |
|
dapagliflozin/metformin (固定剂量复方) |
AstraZeneca， Bristol-Myers Squibb |
2型糖尿病 |
III期临床 | |
|
DC9703 |
Obio Pharmaceutical (Omega BioPharma) |
2型糖尿病 |
I期临床 | |
|
Diamyd(自身免疫糖尿病疫苗) |
Diamyd Medical |
1型糖尿病 |
III期临床 | |
|
DiaPep277 |
Andromeda Biotech |
成人隐匿性自身免疫糖尿病 |
II期临床 | |
|
DSP-8658 |
Dainippon Sumitomo Pharma |
2型糖尿病 |
I期临床 | |
|
EX-1000 |
Novo Nordisk |
2型糖尿病 |
II期临床 | |
|
exenatide(鼻内给药) |
Amylin Pharmaceuticals，MDRNA |
2型糖尿病 |
I期临床完成 | |
|
exenatide |
Alkermes，Amylin Pharmaceuticals，Eli Lilly |
2型糖尿病 |
提交申请 | |
|
exenatide(混悬剂，一周1次) |
Amylin Pharmaceuticals Eli Lilly |
2型糖尿病 |
I/II期临床 | |
|
exenatide(经皮给药制剂) |
Altea Therapeutics， Amylin Pharmaceuticals， Eli Lilly |
2型糖尿病 |
I期临床 | |
|
FGF-21 variant |
Eli Lilly |
2型糖尿病 |
I期临床 | |
|
Galvus(维格列汀，vildagliptin) |
Novartis Pharmaceuticals |
2型糖尿病 |
提交申请 | |
|
Glinsuna(米格列奈，mitiglinide) |
Elixir Pharmaceuticals |
2型糖尿病 |
III期临床完成 | |
|
GLP-1(口服) |
Emisphere Technologies |
2型糖尿病 |
I期临床 | |
|
GLP-1 FC |
Eli Lilly |
2型糖尿病 |
II期临床 | |
|
GLP-1 PEG |
Eli Lilly |
2型糖尿病 |
I期临床 | |
|
HDV-insulin |
Diasome Pharmaceuticals |
2型糖尿病 |
II期临床 | |
|
HE3286 |
HollisEden Pharmaceuticals |
2型糖尿病 |
II期临床 | |
|
HSD016 |
Wyeth Pharmaceuticals |
糖尿病 |
I期临床 | |
|
IL-1抗体 |
Eli Lilly |
2型糖尿病 |
I期临床 | |
|
INCB-13739 |
Incyte |
2型糖尿病 |
II期临床 | |
|
INCB-19602 |
Incyte |
2型糖尿病 |
II期临床 | |
|
INCB-20817 |
Incyte |
2型糖尿病 |
II期临床 | |
|
INGAP peptide |
Kinexum Metabolics |
1型糖尿病 2型糖尿病 |
II期临床完成 | |
|
胰岛素吸入剂(insulin inhalation) |
Baxter Healthcare |
糖尿病 |
I期临床 | |
|
胰岛素吸入剂(insulin inhalation) |
MicroDose Technologies |
糖尿病 |
I期临床完成 | |
|
胰岛素鼻喷剂(insulin nasal spray) |
MDRNA |
2型糖尿病 |
II期临床 | |
|
胰岛素(口服) |
Emisphere Technologies |
2型糖尿病 |
I/II期临床 | |
|
胰岛素(口服) |
Generex Biotechnology |
1型糖尿病 |
III期临床 | |
|
胰岛素(经皮给药制剂) |
Dermisonics |
1型糖尿病 2型糖尿病 |
I期临床 | |
|
INT-131 |
InteKrin Therapeutics |
2型糖尿病 |
II期临床 | |
|
Intesulin(胰岛素，口服) |
Coremed |
糖尿病 |
I期临床 | |
|
|
|
2型糖尿病 (联合用药) |
II期临床 | |
|
ISIS-SGLT2rx |
|
2型糖尿病 |
I期临床 | |
|
JTT-654 |
Akros Pharma |
2型糖尿病 |
I期临床 | |
|
K-111 |
Kowa Pharmaceuticals |
2型糖尿病 |
II期临床 | |
|
KRP-104 |
ActivX Biosciences |
2型糖尿病 |
II期临床 | |
|
larazotide |
Alba Therapeutics |
1型糖尿病 |
I期临床 | |
|
liraglutide(NN2211) |
Novo Nordisk |
2型糖尿病 |
提交申请 | |
|
lisofylline |
DiaKine Therapeutics |
1型糖尿病(新诊断患者) |
I期临床 | |
|
LX-4211 |
Lexicon Pharmaceuticals |
2型糖尿病 |
I期临床 | |
|
LY2599506(葡糖激酶激活剂，glukokinase activator) |
Eli Lilly， OSI Pharmaceuticals |
2型糖尿病 |
I期临床 | |
|
MB07803 |
Metabasis Therapeutics |
2型糖尿病 |
II期临床 | |
|
MBX-102 |
Johnson & Johnson Pharmaceutical Research & Development |
2型糖尿病 |
II/III期临床 | |
|
MBX-2044 |
Johnson & Johnson Pharmaceutical Research & Development |
2型糖尿病 |
II期临床 | |
|
MBX-2982 |
Metabolex |
2型糖尿病 |
I期临床 | |
|
Metgluna(米格列奈/二甲双胍) |
Elixir Pharmaceuticals |
2型糖尿病(联合用药) |
III期临床 | |
|
mitoglitazone(MSDC-0160) |
Metabolic Solutions Development |
2型糖尿病 |
II期临床 | |
|
MK-0893 |
Merck |
2型糖尿病 |
II期临床 | |
|
MK-0941 |
Merck |
2型糖尿病 |
II期临床 | |
|
MK-1006 |
Merck |
糖尿病 |
I期临床 | |
|
MK-4074 |
Merck |
糖尿病 |
I期临床 | |
|
MK-8245 |
Merck |
2型糖尿病 |
I期临床 | |
|
MKC253(GLP-1吸入剂) |
Mannkind |
2型糖尿病 |
I期临床 | |
|
MP-513 |
Mitsubishi Pharma |
2型糖尿病 |
I期临床 | |
|
Nasulin (重组胰岛素鼻腔给药制剂) |
CPEX Pharmaceuticals |
1型糖尿病 2型糖尿病 |
II期临床 | |
|
Naturlose(塔格糖，tagatose) |
Spherix |
2型糖尿病 |
III期临床 | |
|
NBI-6024 |
Neurocrine Biosciences |
1型糖尿病 |
II期临床 | |
|
netoglitazone |
Perlegen Sciences |
2型糖尿病 |
I期临床 | |
|
NN1250 |
Novo Nordisk |
1型糖尿病 2型糖尿病 |
II期临床 | |
|
NN5401 |
Novo Nordisk |
1型糖尿病 2型糖尿病 |
II期临床 | |
|
NN9101 |
Novo Nordisk |
2型糖尿病 |
I期临床 | |
|
NN9535 |
Novo Nordisk |
2型糖尿病 |
II期临床 | |
|
NP-500 |
|
2型糖尿病 |
I期临床 | |
|
OMJPGCGR( |
Isis Pharmaceuticals，Johnson & Johnson Pharmaceuticals Research & Development |
2型糖尿病 |
I期临床 | |
|
Ondero(linagliptin) |
Boehringer Ingelheim Pharmaceuticals |
2型糖尿病 |
III期临床 | |
|
Onglyza(saxagliptin，DPP-4抑制剂) |
AstraZeneca， Bristol-Myers Squibb |
2型糖尿病 |
提交申请 | |
|
ONO-5129 |
Ono Pharma |
2型糖尿病 |
II期临床 | |
|
otelixizumab(罕用药) |
GlaxoSmithKline，Tolerx |
1型糖尿病 |
III期临床 | |
|
PEG裹胰岛细胞移植疗法(PEG-encapsulated islet cell transplantation therapy) |
Novocell，Pfizer |
1型糖尿病 |
I/II期临床 | |
|
PF-734200 |
Pfizer |
2型糖尿病 |
II期临床 | |
|
PF-4325667 |
Pfizer |
糖尿病 |
I期临床 | |
|
PF-4620110 |
Pfizer |
2型糖尿病 |
I期临床 | |
|
PHX-1149(dutogliptin) |
Forest Laboratories，Phenomix |
2型糖尿病 |
III期临床 | |
|
PPM-201 |
Wyeth Pharmaceuticals |
2型糖尿病 |
I期临床 | |
|
PPM-202 |
Wyeth Pharmaceuticals |
2型糖尿病 |
I期临床 | |
|
Prochymal(间质干细胞疗法) |
Osiris Therapeutics |
1型糖尿病 |
II期临床 | |
|
PSN821 |
OSI Pharmaceuticals |
2型糖尿病 |
I期临床 | |
|
pyrazinoyl-guanidine |
SuperGen |
2型糖尿病 |
II期临床 | |
|
R1439(aleglitazar) |
Roche |
2型糖尿病 |
II期临床 | |
|
R1511 |
Roche |
2型糖尿病 |
I期临床 | |
|
R1579(carmegliptin) |
Roche |
2型糖尿病 |
II期临床 | |
|
R1583(taspoglutide) |
Roche |
2型糖尿病 |
III期临床 | |
|
R4929 |
Roche |
2型糖尿病 |
I期临床 | |
|
R7089 |
Roche |
2型糖尿病 |
I期临床 | |
|
R7201 |
Roche |
2型糖尿病 |
I期临床 | |
|
R7234 |
Roche |
2型糖尿病 |
I期临床 | |
|
remogliflozin |
GlaxoSmithKline |
2型糖尿病 |
II期临床 | |
|
rHuPH20 |
Halozyme Therapeutics |
1型糖尿病 |
II期临床 | |
|
rivoglitazone |
Daiichi Sankyo |
2型糖尿病 |
III期临床 | |
|
RO-438857 |
Roche |
2型糖尿病 |
临床研究中 | |
|
RO-4998452 |
Roche |
2型糖尿病 |
II期临床 | |
|
SAR351034(PPAR激动剂) |
Sanofi-Aventis |
2型糖尿病 |
I期临床 | |
|
saxagliptin/二甲双胍(联合疗法) |
AstraZeneca， Bristol-Myers Squibb |
2型糖尿病 |
III期临床 | |
|
sodelglitazar |
GlaxoSmithKline |
2型糖尿病 |
II期临床 | |
|
SRT501 |
Sirtris Pharmaceuticals |
2型糖尿病 |
II期临床 | |
|
SRT2104 |
Sirtris Pharmaceuticals |
2型糖尿病 |
I期临床 | |
|
succinobucol |
AtheroGenics |
2型糖尿病 |
III期临床 | |
|
SUN E7001 (GLP-1(7-36) amide，鼻腔给药) |
Asubio Pharmaceuticals |
2型糖尿病 |
I期临床 | |
|
Symlin(pramlintide) |
Amylin Pharmaceuticals |
1型糖尿病 (青少年) |
II期临床 | |
|
Syncria(albiglutide) |
GlaxoSmithKline |
2型糖尿病 |
III期临床 | |
|
SYR-472 |
Takeda Pharmaceuticals |
2型糖尿病 |
II期临床 | |
|
TA-6666 |
Mitsubishi Pharma |
2型糖尿病 |
II期临床 | |
|
TA-7284(JNJ-28431754) |
Johnson & Johnson Pharmaceutical Research& Development， Mitsubishi Pharma |
2型糖尿病 |
II期临床 | |
|
TAK-379 |
Takeda Pharmaceuticals |
2型糖尿病 |
II期临床 | |
|
TAK-875 |
Takeda Pharmaceuticals |
2型糖尿病 |
I期临床 | |
|
teplizumab(罕用药) |
Eli Lilly，Macrogenics |
1型糖尿病 |
III期临床 | |
|
trodusquemine |
Genaera |
2型糖尿病 |
I期临床 | |
|
TTP355 |
TransTech Pharma |
2型糖尿病 |
I期临床 | |
|
VGX-1027 |
VGX Pharmaceuticals |
1型糖尿病 |
I期临床完成 | |
|
VIAject(胰岛素注射剂) |
Biodel |
1型糖尿病 2型糖尿病 |
III期临床完成 | |
|
VIAtab(胰岛素舌下给药) |
Biodel |
1型糖尿病 |
I期临床 | |
|
vildagliptin/二甲双胍(复方) |
Novartis Pharmaceuticals |
2型糖尿病 |
提交申请 | |
|
XOMA052 |
XOMA |
2型糖尿病 |
I期临床 | |
|
YM543 |
Astellas Pharma |
2型糖尿病 |
II期临床 | |
2 糖尿病相关性疾病
|
产品名称 |
公司 |
适应证 |
研发阶段 |
|
aflibercept(VEGF-trap) (玻璃体腔内注射) |
Bayer HealthCare Pharmaceuticals，Regeneron Pharmaceuticals |
糖尿病黄斑水肿 |
II期临床 |
|
Arxxant(ruboxistaurin) |
Alcon，Eli Lilly |
糖尿病视网膜病变 |
提交申请 |
|
AS3201 |
Eisai |
糖尿病性神经病变 |
II期临床 |
|
ATG-3 |
CoMentis |
糖尿病黄斑水肿 |
II期临床 |
|
AZD2066 |
AstraZeneca |
痛性糖尿病性神经病变 |
II期临床 |
|
ICO-007 |
iCo Therapetics |
糖尿病黄斑水肿 |
I期临床 |
|
Iluvien(醋酸肤轻松眼用制剂) |
Alimera Sciences |
糖尿病黄斑水肿 |
III期临床 |
|
indantadol(V3881) |
Vernanlis |
痛性糖尿病性神经病变 |
II期临床 |
|
Lucentis(ranibizumab) |
Genentech |
糖尿病黄斑水肿 |
III期临床 |
|
Macugen(pegaptanib) |
OSI Eyetech，Pfizer |
糖尿病黄斑水肿, 糖尿病视网膜病变 |
III期临床 |
|
NGX-4010 |
NeurogesX |
糖尿病性神经病变 |
II期临床 |
|
Nova 63035 |
Novagali Pharma |
糖尿病黄斑水肿 |
I期临床 |
|
PF-4523655 |
Pfizer |
糖尿病黄斑水肿 |
II期临床 |
|
PF-4856880(ADL5859) |
Adolor，Pfizer |
痛性糖尿病性周围神经病变 |
II期临床 |
|
Posurdex (地塞米松眼用制剂) |
Allergan |
糖尿病黄斑水肿 |
III期临床 |
|
sirolimus ophthalmic(西罗莫司眼用制剂) |
MacuSight |
糖尿病黄斑水肿 |
II期临床 |
|
糖尿病黄斑水肿(玻璃体腔内注射) |
I期临床 | ||
|
Solzira(加巴喷丁， gabapentin enacarbil) |
GlaxoSmithKline，XenoPort |
糖尿病性神经病变 |
II期临床 |
|
SSR180575(PBR ligand) |
Sanofi-Aventis |
糖尿病多发性神经病变 |
II期临床 |
|
Vitreosolve(糖尿病视网膜病变疗法) |
Vitreoretinal Technologies |
糖尿病视网膜病变 |
III期临床 |